Who executed the Clene (CLNN) share sales disclosed in this Form 4?

The transactions are attributed to Symbiosis II, LLC, an entity through which reporting person Ugwumba Chidozie holds Clene shares indirectly. Each transaction is marked as indirect ownership with the nature of ownership described as "By Symbiosis II, LLC" in the filing.

Clene insider entity sells 100,997 shares

Clene Inc. ten-percent owner Ugwumba Chidozie, through Symbiosis II, LLC, reported open-market sales of Clene common stock.

Accepted by SEC EDGAR 03/31/2026 - 04:35 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Clene Inc. ten-percent owner Ugwumba Chidozie, through Symbiosis II, LLC, reported open-market sales of Clene common stock. The LLC sold 67,991 shares at $4.88, 15,536 shares at $5.10, and 17,470 shares at $4.75 per share. Following these transactions, Symbiosis II, LLC continued to hold 431,094 shares of Clene common stock indirectly attributed to Chidozie.

Insider Trade Summary

Net Seller: 100,997 shares

Net Sell 3 txns

Insider Ugwumba Chidozie

Role 10% Owner

Sold 100,997 shs ($494K)

Type	Security	Shares	Price	Value
Sale	Common Stock	67,991	$4.88	$332K
Sale	Common Stock	15,536	$5.10	$79K
Sale	Common Stock	17,470	$4.75	$83K

Holdings After Transaction: Common Stock — 431,094 shares (Indirect, By Symbiosis II, LLC)

Key Figures

Total shares sold: 100,997 shares Sale 1 size and price: 67,991 shares at $4.88 Sale 2 size and price: 15,536 shares at $5.10 +3 more

6 metrics

Total shares sold 100,997 shares Aggregate open-market sales reported in Form 4

Sale 1 size and price 67,991 shares at $4.88 Common stock sale on 2026-03-31

Sale 2 size and price 15,536 shares at $5.10 Common stock sale on 2026-03-30

Sale 3 size and price 17,470 shares at $4.75 Common stock sale on 2026-03-27

Shares held after latest sale 431,094 shares Indirect holdings by Symbiosis II, LLC after 2026-03-31

Net share change -100,997 shares Net sell direction in transaction summary

Key Terms

open-market sale, ten percent owner, indirect ownership, non-derivative, +1 more

5 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

ten percent owner regulatory

""is_ten_percent_owner": 1"

indirect ownership financial

""ownership_type": "indirect""

non-derivative financial

""transaction_type": "non-derivative""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Clene (CLNN) report in this Form 4?

The filing shows a ten-percent owner associated with Clene completed three open-market sales of common stock through Symbiosis II, LLC, totaling 100,997 shares over several days, with all transactions coded as open-market sales of non-derivative common stock.

How many Clene (CLNN) shares were sold and at what prices?

Symbiosis II, LLC sold 67,991 Clene shares at $4.88, 15,536 shares at $5.10, and 17,470 shares at $4.75. Altogether, the entity disposed of 100,997 common shares in open-market transactions according to the Form 4 transaction summary.

How many Clene (CLNN) shares remain held after these insider sales?

After the latest reported sale, Symbiosis II, LLC held 431,094 Clene common shares indirectly for reporting person Ugwumba Chidozie. This post-transaction balance is disclosed in the Form 4 as the total number of shares beneficially owned following the transaction.

What do the Form 4 transaction codes mean for Clene (CLNN)?

Each transaction uses code "S," which the Form 4 describes as a sale in an open market or private transaction. The filing also labels the transaction action as an open-market sale of non-derivative common stock rather than an option exercise or other derivative event.

Does this Clene (CLNN) Form 4 involve derivative securities or just common stock?

The reported transactions all involve non-derivative Clene common stock. The derivative summary section in the data is empty, indicating no option exercises, warrant conversions, or other derivative transactions were reported in this particular Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last)

(First)

(Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE

ARKANSAS

72712

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/27/2026		S		17,470	D	$4.75	514,621	I	By SymBiosis II, LLC
Common Stock	03/30/2026		S		15,536	D	$5.1	499,085	I	By SymBiosis II, LLC
Common Stock	03/31/2026		S		67,991	D	$4.88	431,094	I	By Symbiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Chidozie Ugwumba	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR